Myllia Biotechnology is a biotech company unlocking the power of CRISPR and singlecell transcriptomics to explore gene function at scale in primary human cells. With a focus on immune cells, Myllia’s VISTA™ platform enables the discovery of high-value drug targets and deep insights into immune cell function. Myllia has built an end-to-end genetic screening platform in primary human cells and cancer cell lines.